Status:
COMPLETED
A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension-
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Bone Marrow Transplantation
Graft Versus Host Disease
Eligibility:
All Genders
20-54 years
Phase:
PHASE2
Brief Summary
To assess safety and efficacy of the patients with MR4 therapy in GVHD prophylaxis study who are eligible for the administration after 100 days post transplant (up to 1 year)
Eligibility Criteria
Inclusion
- Patient had enrolled in GVHD prophylaxis study.
- Patient had been fully informed.
Exclusion
- The patient had been not eligible for the administration after 100 days post transplant in the investigator's judgement.
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00189748
Start Date
August 1 2004
Last Update
September 20 2006
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Chubu Region, Japan
2
Hokkaido Region, Japan
3
Kanto Region, Japan
4
Kyusyu Region, Japan